EGFR and non-small cell lung carcinoma: Compared with epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, the genetic proto-oncogene tyrosine-protein kinase-1 (ROS1) is less prevalent in NSCLC, accounting for approximately 0.9%–2.6% of cases (Bergethon et al., 2012; Cai et al., 2013).